Skip to main content
SpringerLink
Log in

Inhibition of Human Glioma Cell Growth by a PHS-2 Inhibitor, NS398, and a Prostaglandin E Receptor Subtype EP1-selective Antagonist, SC51089

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Prostaglandin H synthase (PHS) is a key enzyme in the synthesis of prostaglandins (PGs). Recently, enhanced expression of PHS-2 in brain tumors and the correlation between the PHS-2 level and the histopathological grade of glioma has been reported. Furthermore, in vitro inhibition of glioma cell growth by a specific PHS-2 inhibitor, NS398, has been demonstrated. It has also been shown that prostaglandin E2 (PGE2) contributes to colon carcinogenesis by binding to the prostaglandin E receptor subtype EP1. We therefore evaluated the effects of NS398 and two EP1 antagonists, SC51089 and AH6809, on glioma cell lines.

To evaluate mechanisms of NS398's action, two glioma cell lines, a PHS-2–positive cell line (KMG4) and a PHS-2-deficient cell line (A172), were used. NS398 inhibited both the anchorage-dependent and -independent growth of glioma cell lines regardless of PHS-2 expression, suggesting that some PHS-2-independent mechanisms underlie the antineoplastic effect of NS398. However, the antineoplastic effect was attenuated by the addition of PGE2, which is one of the main products of PHS, suggesting the predominant mechanism is PHS-dependent. The EP1 antagonists, SC51089 and AH6809, inhibited the growth of glioma cell lines in vitro. Furthermore, NS398 or SC51089 slowed tumor growth in vivo, which was assessed using KMG4 tumor xenografts on SCID mice. PHS-2 inhibitors and EP1 antagonists might be useful in the prevention and/or treatment of glioma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, Dubois RN: Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188, 1994

    Google Scholar 

  2. Kutchera W, Jones DA, Matsunami N, Groden J, McIntyre TM, Zimmerman GA, White RL, Prescott SM: Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci USA 93: 4816-4820, 1996

    Google Scholar 

  3. Smalley W, DuBois RN: Colorectal cancer and non steroidal anti-inflammatory drugs. Adv Pharmacol 39: 1-20, 1997

    Google Scholar 

  4. Deininger MH, Weller M, Streffer J, Mittelbronn M, Meyermann R: Patterns of cyclooxygenase-1 and-2 expression in human gliomas in vivo. Acta Neuropathol(Berl) 98: 240-244, 1999

    Google Scholar 

  5. Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF: Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res 61: 4375-4381, 2001

    Google Scholar 

  6. Matsuo M, Yonemitsu N, Zaitsu M, Ishii K, Hamasaki Y, Fukuyama K, Tabuchi K, Miyazaki S: Expression of prostaglandin H synthase-2 in human brain tumors. Acta Neuropathol(Berl) 102: 181-187, 2001

    Google Scholar 

  7. Joki T, Heese O, Nikas DC, Bello L, Zhang J, Kraeft S-K, Seyfried NT, Abe T, Chen LB, Caroll RS, Black PM: Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS398. Cancer Res 60: 4926-4931, 2000

    Google Scholar 

  8. Chan TA, Morin PJ, Vogelstein B, Kinzler KW: Mechanism underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 95: 681-686, 1998

    Google Scholar 

  9. Zang X, Morham SG, Langenbach R, Young DA: Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med 190: 451-459, 1999

    Google Scholar 

  10. Smith M-L, Hawcroft G, Hull MA: The effect of nonsteroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Eur J Cancer 36: 664-674, 2000

    Google Scholar 

  11. Watanabe K, Kawamori T, Nakatsugi S, Ohta T, Ohuchida S, Yamamoto H, Maruyama T, Kondo K, Ushikubi F, Narumiya S, Sugimura T, Wakabayashi K: Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res 59: 5093-5096, 1999

    Google Scholar 

  12. Zaitsu M, Hamasaki Y, Matsuo M, Miyazaki M, Hayasaki R, Muro E, Yamamoto S, Kobayashi I, Ichimaru T, Miyazaki S: Induction of cytosolic phospholipase A2 and prostaglandin H2 synthase-2 by lipopolysaccharide in human polymorphonuclear leukocytes. Eur J Haematol 62: 1-9, 1999

    Google Scholar 

  13. Aas AT, Tonnessen TI, Burn A, Salford LG: Growth inhibition of rat glioma cells in vitro and in vivo by aspirin. J Neuro-Oncol 24: 171-180, 1995

    Google Scholar 

  14. Farrell CL, Megiesi J, Del Maestro RF: Effect of ibuprofen on tumor growth in the C6 spheroid implantation glioma model. J Neurosurg 68: 925-930, 1988

    Google Scholar 

  15. Wilson DE, Anderson KM, Seed TM: Ultrastructural evidence for differentiation in a human glioblastoma cell line treated with inhibitors of eicosanoid metabolism. Neurosurgery 27: 523-531, 1990

    Google Scholar 

  16. Reddy BS, Maruyama H, Kelloff G: Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal anti-inflammatory drug, during different stages of rat colon tumor development. Cancer Res 47: 5340-5346, 1987

    Google Scholar 

  17. Fulton AM: in vivo effects of indomethacin on the growth of murine mammary tumor. Cancer Res 44: 2416-2420, 1984

    Google Scholar 

  18. Duperron C., Castonguay A: Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carcinogenesis 18: 1001-1006, 1997

    Google Scholar 

  19. Partignani P, Santini G, Sciulli MG, Marinacci R, Fusco O, Spoletini L, Natoli C, Procopio A, Maclouf J: Cyclooxygenase-independent induction of p21 WAF-1/CIP-1, apoptosis and differentiation by L-745,337 and salicylate in HT-29 colon cancer cells. Adv Exp Med Biol 469: 555-561, 1999

    Google Scholar 

  20. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA: Peroxisome proliferator-activated receptors a and g are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272: 3406-3410, 1997

    Google Scholar 

  21. McEntee MF, Chue C-H, Whelan J: Relationship of β-catenin and Bcl-2 expression to sulindac-induced regression of intestinal tumors in Min mice. Carcinogenesis 20: 635-640, 1999

    Google Scholar 

  22. Mahmoud NN, Boolbol SK, Billinski RT, Martucci C, Chadburn A, Bertagnolli MM: Apc gene mutation is associated with dominant-negative effect upon intestinal cell migration. Cancer Res 57: 5045-5050, 1997

    Google Scholar 

  23. Schmelz EM, Bushnev AS, Dillehay DL, Sullards MC, Liotta DC, Merrill AH. Jr: Ceramide-b-D-glucronide. Synthesis, digestion, and suppression of early markers of colon carcinogenesis. Cancer Res 59: 5768-5772, 1999

    Google Scholar 

  24. Shureiqi I, Chen D, Lotan R, Yang P, Newman RA, Fischer SM, Lippman SM: 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res 60: 6846-6850, 2000

    Google Scholar 

  25. Thompson WJ, Piazza GA, Li H, Liu L, Fetter J, Zhu B, Sperl G, Ahnen D, Pamukcu R: Exisulind induction of apoptosis involves guanosine 3′,5′-cyclicmonophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated b-catenin. Cancer Res 60: 3338-3342, 2000

    Google Scholar 

  26. Raz A: Is inhibition of cyclooxygenase required for the anti-tumorigenic effects of nonsteroidal, antiinflammatory drugs (NSAIDs)? in vitro versus in vivo results and the relevance for the prevention and treatment of cancer. Biochem Pharmacol 63: 343-347, 2002

    Google Scholar 

  27. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705-716, 1998

    Google Scholar 

  28. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN: Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105: 1589-1594, 2000

    Google Scholar 

  29. Barnett J, Chow J, Ives D, Chiou M, Mackenzie R, Osen E, Nguyen B, Tsing S, Bach C, Freire J, Chan H, Sigal E, Ramesha C: Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. Biochim Biophys Acta 1209: 130-139, 1994

    Google Scholar 

  30. Sheng H, Shao J, Morrow JD, Beauchamp RD, Dubois RN: Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 58: 362-366, 1998

    Google Scholar 

  31. Hansen-Petrik MB, McEntee MF, Jull B, Shi H, Zemel MB, Whelan J: Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. Cancer Res 62: 403-408, 2002

    Google Scholar 

  32. Lehnert T, Deschner EE, Karmali RA, DeCosse JJ: Effect of flurbiprofen and 16,16-demethyl prostaglandin E2 on gastrointestinal tumorigenesis induced by N-methyl-N'-nitrosoguanidine in rats: glandular epithelium of stomach and duodenum. Cancer Res 50: 381-384, 1990

    Google Scholar 

  33. Wilson JW, Potten CS: The effect of exogenous prostaglandin administration on tumor size and yield in Min/+ mice. Cancer Res 60: 4645-4653, 2000

    Google Scholar 

  34. Mutoh M, Watanabe K, Kitamura T, Shoji Y, Takahashi M, Kawamori T, Tani K, Kobayashi M, Maruyama T, Kobayashi K, Ohuchida S, Sugimoto Y, Narumiya S, Sugimura T, Wakabayashi K: Involvement of prostaglandin E receptor subtype EP4 in colon carcinogenesis. Cancer Res 62: 28-32, 2002

    Google Scholar 

  35. Kawamori T, Uchiya N, Nakatsugi S, Watanabe K, Ohuchida S, Yamamoto H, Maruyama T, Kondo K, Sugimura T, Wakabayashi K: Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. Carcinogenesis 22: 2001-2004, 2001

    Google Scholar 

  36. Casibang M, Moody TW: AH6809 antagonizes non-small cell lung cancer prostaglandin receptors. Lung Cancer 36: 33-42, 2002

    Google Scholar 

  37. Sanchez T, Moreno JJ: Role of EP(1) and EP(4)PGE(2) subtype receptors in serum-induced 3T6 fibroblast cycle progression and proliferation. Am J Physiol Cell Physiol 282: C280-C288, 2002

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Saga Medical School, Saga, Japan

    Muneaki Matsuo, Nobuyuki Yoshida, Masahumi Zaitsu, Kiyohisa Ishii & Yuhei Hamasaki

Authors
  1. Muneaki Matsuo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nobuyuki Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masahumi Zaitsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kiyohisa Ishii
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuhei Hamasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Matsuo, M., Yoshida, N., Zaitsu, M. et al. Inhibition of Human Glioma Cell Growth by a PHS-2 Inhibitor, NS398, and a Prostaglandin E Receptor Subtype EP1-selective Antagonist, SC51089. J Neurooncol 66, 285–292 (2004). https://doi.org/10.1023/B:NEON.0000014537.15902.73

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:NEON.0000014537.15902.73

Search

Navigation